Literature DB >> 15077278

Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.

Ennio Giulio Favalli, Marco Arreghini, Cristina Arnoldi, Benedetta Panni, Antonio Marchesoni, Sergio Tosi, Irene Pontikaki.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15077278     DOI： 10.1002/art.20242

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  10 in total

1.  Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: experience from a large U.S. cohort.

Authors:  Jie Zhang; Ying Shan; George Reed; Joel Kremer; Jeffrey D Greenberg; Scott Baumgartner; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-12       Impact factor: 4.794

2.  Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue.

Authors:  Ronald F van Vollenhoven
Journal:  Ann Rheum Dis       Date:  2007-07       Impact factor: 19.103

3.  Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study.

Authors:  Daniel E Furst; Norman Gaylis; Vance Bray; Ewa Olech; David Yocum; Jeffrey Ritter; Michael Weisman; Daniel J Wallace; John Crues; Dinesh Khanna; Gregory Eckel; Newman Yeilding; Peter Callegari; Sudha Visvanathan; Jeannie Rojas; Ronald Hegedus; Laura George; Khalid Mamun; Keith Gilmer; Orrin Troum
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

4.  Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort.

Authors:  Ennio G Favalli; Andrea Becciolini; Antonio Carletto; Fabrizio Conti; Giorgio Amato; Enrico Fusaro; Luca Quartuccio; Colin Gerard Egan; Andrea Lo Monaco; Maurizio Benucci; Fausto Salaffi; Angelo Semeraro; Simone Parisi; Fulvia Ceccarelli; Ilaria Piazza; Rosario Foti
Journal:  Rheumatol Int       Date:  2019-08-21       Impact factor: 2.631

5.  Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab.

Authors:  María M Katsicas; Ricardo A G Russo
Journal:  Clin Rheumatol       Date:  2009-03-26       Impact factor: 2.980

Review 6.  Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.

Authors:  Susan Shenoi; Carol A Wallace
Journal:  Paediatr Drugs       Date:  2010-12-01       Impact factor: 3.022

Review 7.  Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists.

Authors:  Joseph R Lutt; Atul Deodhar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.

Authors:  Juan J Gomez-Reino; Loreto Carmona
Journal:  Arthritis Res Ther       Date:  2006-01-06       Impact factor: 5.156

9.  Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis.

Authors:  Alberto Migliore; Giuseppe Pompilio; Davide Integlia; Joe Zhuo; Evo Alemao
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-03-29       Impact factor: 5.346

10.  DAS-28-based EULAR response and HAQ improvement in rheumatoid arthritis patients switching between TNF antagonists.

Authors:  Federico Navarro-Sarabia; Dolores Ruiz-Montesinos; Blanca Hernandez; Victoria Navarro-Compán; Sara Marsal; Mireia Barcelo; Eva Perez-Pampín; Juan J Gómez-Reino
Journal:  BMC Musculoskelet Disord       Date:  2009-07-23       Impact factor: 2.362
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.